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expanded services and mandating quality. Studies show that wellness programs are 
growing in number and in various sizes, services, and incentives resulting in a signif-
icant to non-significant return-on-investment (ROI). Few employers have measured 
the ROI and even fewer their health outcomes. However, successful programs have 
shown a median ROI between 2:1 and 3:1. Studies suggest that disease-management 
services account for significantly positive ROI while lifestyle management services 
do not. For example, the partnership between Piedmont and WellStar of Georgia 
supported implementation of care-management programs, with higher quality at 
lower costs. CONCLUSIONS: Although most are not reporting ROI, studies show the 
value of wellness programs should be based on health outcomes.
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OBJECTIVES: The study objective was to estimate the causal effect of the publication 
of drug-specific clinical and health economic and outcomes research (HEOR) publica-
tions on US drug product sales. METHODS: Quarterly sales data for twenty-two drugs, 
(biologics for rheumatoid arthritis (RA), new generation asthma drugs and statins) 
and contemporaneous publication counts of HEOR, clinical and meta-analytic stud-
ies via literature search were analyzed. Clinical studies were categorized by journal 
impact factor. The total analysis period spanned 2003-2013, with drug-specific expo-
sure varying based on its branded status over that timeframe. Covariates included 
generic availability, safety warnings, and new indications (as a proxy for sales effort). 
First difference and difference in first difference fixed effects models were used to 
control for unobserved time invariant and constant-rate time-variant unobserved 
confounders and estimate the causal effect of an additional study in a given quarter 
and the increase in sales in the next quarter. RESULTS: In the statin market, the 
potential casual effect of an HEOR study publication on next quarter’s sales was 
$1 - $2.2 million. High-impact clinical publication also significantly increased sales 
in the next quarter (~$7 million). In RA and asthma markets, HEOR studies were not 
statistically linked to quarterly sales, but high-impact clinical studies were found 
to have significant effects on asthma drug sales in the next quarter (~$7.5 million). 
Meta-analyses were only found to have a significant effect on RA drugs sales (~$3.5 
million). CONCLUSIONS: Impact of publications on sales varied. Both HEOR and high-
impact clinical studies were associated with an increase in quarterly sales in the 
statin market, where generic competition is high. These effects were seen to a lesser 
degree in the statin and RA markets, where generic competition is lower. Market 
characteristics that vary across the studied classes, such as branded and generic 
competition, may dictate returns from HEOR and clinical studies.
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OBJECTIVES: Prescription claims databases are used for identifying patients for dis-
ease management programs and studying health outcomes. The growth in the use 
of drug samples and discount generic programs suggests that an increasing number 
of prescriptions dispensed to insured consumers may not be captured on claims 
databases. We examined the extent to which prescription claims databases do not 
provide complete records of insured patients’ drug use and report the top 5 drug 
classes that were dispensed as drug samples and discount generics. METHODS: We 
used the 2012 Medical Expenditure Panel Survey (MEPS) dataset. We included par-
ticipants who purchased at least one prescription medication and had prescription 
drug insurance for 2012. We quantified the extent to which insured patients used 
drug samples and/or discount generics. We reported descriptive statistics. We used 
Enhanced Therapeutic Classification (ETC) codes to report the top 5 drug classes that 
were dispensed as drug samples and discount generics. RESULTS: A total of 78.6% of 
the U.S. non-institutionalized civilian population was insured for prescription drugs. 
Of the total number of prescriptions dispensed to insured consumers, at least 0.5% 
were drug samples and 4.8% were potentially discount generics. Additionally, 8% of 
insured consumers received at least one sample medication and 21.5% used at least 
one potential discount generic product. The top 5 drug classes dispensed as drug 
samples in descending order were statins, Angiotensin Converting Enzyme (ACE) 
inhibitors, beta-blockers (cardiac selective), Selective Serotonin Reuptake Inhibitors 
(SSRIs) and Proton Pump Inhibitors (PPIs). The top 5 drug classes dispensed as dis-
count generics in descending order were statins, ACE inhibitors, SSRIs, beta-blockers 
(cardiac selective) and PPIs. CONCLUSIONS: Our results indicate that drug samples 
do not contribute substantially to the problem of missing prescription data on claims 
databases. A substantial number of prescriptions that are discount generics may be 
missing from these databases.
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OBJECTIVES: While all pharmaceutical organizations are held accountable for dis-
seminating scientific literature supporting their product’s health economics and 
outcomes (HEOR) data, it is not known whether professionals in HEOR agree on the 
quality of materials being disseminated; nor do we know how often these documents 
are developed internally or outsourced. Therefore, the objective of this study was to 
assess the perceived level of quality of the materials as well as who is developing the 
ferent amounts per health category even after adjusting for population size and 
needs. CONCLUSIONS: The cluster analysis indicates that the health areas cannot 
be considered to behave similarly to one another, since there is more than one 
cluster in each year and the clusters are stable over time.
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OBJECTIVES: The objective is to provide data support for government decision-
making by having a general view of the status of disease composition, patient 
flow and use of drug and treatment of inpatients with basic medical insurance in 
cities and towns based on sample survey on the medical service utilization and 
payment of such inpatients from 2010 to 2012. METHODS: Sort all patients by 
the time of being released, according to systematic sampling method, extract a 
certain proportion of the insured patients’ hospitalizing information in sampling 
area. Then project the sample data to the country. Retrospective study using SQL 
server and related software. RESULTS: Total hospitalization expenses under urban 
basic medical insurance increased every year, reaching RMB425.3 billion in 2012, 
got 67.77% increase compared with 2010. Expenses increased primarily due to the 
growth of person-time in receiving treatment. The patient-time in receiving treat-
ment reached 4945 times in 2012, 57.18% increases over 2010. In 2012 the average 
hospitalization expenses amounted to RMB8,601, an increase of 6.75% compared 
with RMB8,057 in 2010. Diseases in circulatory, respiratory, and digestive system 
as well as tumor remain the top four most afflicted, accounting for about 60% of 
the total inpatient population. In the disease sub-category, the three most com-
mon diseases accounted for more than 20% of total diseases in patient-times. 
Due to strengthened clinical management of antibiotics use, expense of systimic 
anti-biotics decreased year by year, with 22.46% in 2012, significantly lower than 
28.99% in 2010. CONCLUSIONS: With the establishment and improvement of 
national health insurance, the needs for medical service of insured patients were 
met with substantive effect, but the resulting pressure on fund spending should 
be given more attention. With the continuous attention to the rational clinical 
treatment, irrationality of clinical medication use has improved, but there still 
remains room to improve.
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OBJECTIVES: This study examines disease-specific spending across the full range 
of conditions to identify which conditions are driving the growth in overall spend-
ing in recent years. METHODS: Truven Health MarketScan data for 8M employees 
and their dependents in FFS plans in 2007 and 12M in 2012 are analyzed. The 
samples were weighted to reflect the demographic composition of all US employer 
health plans in those years (as captured by the US Medical Expenditure Panel 
Survey). Total health care spending for each patient was allocated across diseases 
using the Medical Episode Grouper (MEG). MEG allocates the 16,000 ICD9 diagno-
sis codes into 572 conditions. Drug spending is assigned to conditions based on 
clinical logic. Adjudicated payments were summed for each episode type that a 
patient experienced. Analysis focused on absolute change in level of per member 
per year (PMPY) spending (total and out-of-pocket) from 2007 to 2012. We exam-
ined the contributions of disease prevalence and cost per case. RESULTS: PMPY 
spending grew 3.8% per year between 2007 and 2012. Hospital outpatient spending 
grew faster (5.9%) than other settings and prescription drug spending was lower 
(1.7%). The top 10 conditions account for 32% of all spending growth. Preventive 
health services drove up spending by $73 PMPY and was the number 1 driver of 
increased spending. Deliveries, both vaginal and Cesarean Section were in the top 
10. So too were four conditions where obesity is an aggravating factor. Cost per 
case was much more of growth driver than changes in treated prevalence. 2013 
results will be available for presentation. CONCLUSIONS: Administrative data 
when handled carefully can provide a broad overview of changing healthcare 
landscape. The modest cost growth for this population has been widely shared 
across many conditions.
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OBJECTIVES: The Affordable Care Act (ACA) initiated healthcare reforms that stress 
“triple aim” goals: improving patient care, population health, and reducing costs. 
Hospitals are forming mergers and have expanded their employee health and 
wellness programs. The objectives are to (1) summarize the literature on mergers, 
health outcomes, and cost-containment (2) describe value for money of health and 
wellness programs, and (3) provide examples of successful mergers. METHODS: A 
systematic review was conducted to identify the costs and benefits of mergers and 
wellness programs. Articles after 2008 were compiled using search engines PubMed, 
Galileo, Ebscohost, and Google Scholar. Key terms were “value for money”, “corpo-
rate”, “health and wellness program”, “health plan”, “insurance plan”, “hospital”, 
and “merger.” Exclusion criteria were articles involving forms of consolidation and 
wellness programs not tied to insurance plans and without reported costs and/or 
health outcomes. RESULTS: A total of 29 relevant articles were retrieved. Findings 
revealed mergers prevent hospitals from trading-off quality and services for cost 
reductions. However, studies suggest that anticompetitive effects of mergers will 
increase costs. Before the ACA, employers had wellness programs that were not 
standardized. The ACA encouraged improvement of these programs by funding 
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OBJECTIVES: Economic evaluations (EE) are ubiquitous and growing in importance 
with increasing demand for healthcare services. However, healthcare decision 
makers often do not use this evidence when making decisions. Previous research 
has shown several factors influence the use of EE, such as credibility, complexity, 
and timeliness. However, no research has examined the relative importance of 
these factors in making EE more valuable as a service. This research shows what 
factors are most important to healthcare professionals/ administrators/research-
ers, when examining research using EE. METHODS: Study 1, an online question-
naire of Australian infection control practitioners (N= 35), sought ratings of the 
absolute and relative importance of a range of barriers and facilitators of using 
EE in healthcare decision making. Seven factors (rigor of the cost effectiveness 
analysis, quality of the clinical evidence, timeliness, communication, applicabil-
ity, conflicts of interest, equity) were selected from this study to inform Study 2. 
Study 2 used a discrete choice experiment (blocked, orthogonal design) to examine 
the relative importance of these seven factors in the choice between two health 
economists which differ in these attributes. This was administered online to a 
range of Australian healthcare decision makers. RESULTS: Study 1 showed that 
quality of clinical evidence was the most important factor when examining EE, 
followed by applicability, communication, and the rigour of the cost effectiveness 
analysis. Conflict of interest was the least important factor. Study 2 will demon-
strate the trade-offs between these factors. The results for this second study will 
be ready in March. CONCLUSIONS: This research shows which factors are most 
valuable for healthcare decision makers using EE. To our knowledge this is the 
first study to use a preference analytic technique to measure what is valuable in 
a decision tool. The findings from this research will provide guidance on how to 
better deliver EE to end users.
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OBJECTIVES: Public health policies rely largely on observational studies developed 
through the compilation of real world data. From the access and health technol-
ogy assessment (HTA) perspectives, real world data are an essential ancillary tool 
in decision-making, providing information on burden of disease, cost-of-illness, 
resource usage, treatment patterns, compliance, natural history of the disease, 
effectiveness and safety. The Brazilian Network for Health Technology Assessment 
(REBRATS) recommends the use of observational studies to develop economic 
evaluations for both effectiveness and safety data. However, the extent of use 
of such data in Brazil remains undetermined. Our objective was to identify the 
requirements and needs for epidemiological data regarding HTA submissions in 
Brazil. METHODS: We reviewed HTA requirements, reports and dossiers from the 
Brazilian HTA commission (CONITEC) for epidemiological data aimed at incor-
poration. Additionally, we searched Brazilian guidelines and regulations about 
principles for real world data requirements for HTA. RESULTS: CONITEC issued 
119 reports between the time of its establishment (April/2011) and the date of 
our analysis (December 08th, 2014). The Committee reported lack of real world 
studies in 11.8% of the submissions (14 of 119 reports), including the need of 
epidemiological studies (prevalence and incidence) (n= 8), safety and efficacy tri-
als (n= 3), safety study (n= 1), epidemiological and clinical characteristics studies 
(n= 1) and resource use and cost-of-illness analyses (n= 1). The lack of epidemio-
logic data was the most common issue (8 of 14 reports). However, real world data 
regarding safety, effectiveness and clinical characteristics were also critical (7 of 
14 reports). CONCLUSIONS: Our analysis showed that use of real world data in 
Brazil remains an unmet need for HTA.
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OBJECTIVES: Low cost generic programs (LCGPs) offer an affordable means to 
obtain medications which can be used to treat a myriad of acute and chronic 
conditions. However, since the medications are often purchased without using 
insurance, a claim will never be adjudicated. Thus, medication use may go unob-
served in administrative claims data, which are often used for research and quality 
control initiatives. This study sought to assess the characteristics and prevalence 
associated with LCGP use in the Medicare insured population. METHODS: Using 
data from the Medical Expenditure Panel Survey from 2006-2011, individuals 
were classified as LCGP users or non-users based on payment variables from 
pharmacy records. Demographics of users and non-users were compared includ-
ing age, gender, prescription drug coverage, and health-related characteristics. 
A multivariable logistic regression model was estimated to identify the charac-
teristics with the greatest association with use. RESULTS: With a total cohort of 
N= 9,906, 48.03% were classified as users. Half of the individuals with prescrip-
tion insurance coverage utilized these programs compared to nearly one-third 
of those without prescription coverage. The user group also used more medi-
cations per-person over the two-year period (77.20 vs 53.35, p< 0.01) and more 
unique medications (12.68 vs 8.71, p< 0.01). The user group also had higher 
average Charlson Comorbidity Index scores (1.75 vs 1.30, p< 0.01). In adjusted 
analyses, individuals with prescription insurance had 39% higher odds of using 
LCGPs. Each additional unique medication was associated with a 9% increase in 
the odds of being a user (OR 1.09, 95% CI 1.08 – 1.10). LCGP use was also associ-
ated with increasing income levels but not associated with increasing comor-
bidity scores. CONCLUSIONS: Nearly one-half of all Medicare insured persons 
used LCGPs during the study period. This may misrepresent exposure classifi-
cation when research or quality initiatives are based on administrative claims 
data.
materials for dissemination. METHODS: We surveyed HEOR professionals to gauge 
their perspective on the quality of HEOR communications materials. A 16-question 
on-line survey was sent to 300 HEOR professionals in July 2014. Descriptive analyses 
were conducted as appropriate. RESULTS: Fifty-nine surveys were returned fully or 
partially completed. Eighty-eight percent of respondents have advanced degrees, 
43% are employed by bio/pharma companies, 78% are HEOR directors or manag-
ers and 50% had more than 3 years in their current position. Forty-seven percent 
of respondents use internal medical writing teams and 62% subcontract writing to 
outside vendors. Dossiers are the most frequent item outsourced at 45%. Forty percent 
of respondents indicated that they outsource manuscripts and 25% of respondents 
outsource abstracts. Consistently across several quality measures, approximately 
55% of respondents are not satisfied with the quality of writing for their communi-
cation materials. Improvement in value messaging and methodology were the two 
most cited areas of concern about writing quality beyond the general question about 
satisfaction with overall writing quality. CONCLUSIONS: More than 50% of HEOR 
executive respondents seek better quality in written documents and more appropri-
ate terminology in addressing their business objectives with scientifically rigorous 
content. Therefore, it is apparent from these survey results that HEOR directors and 
managers consider nearly half of all their communications to not be well-written.
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OBJECTIVES: Effective communication of risk of medication side effects is neces-
sary in order to minimize its misinterpretation and over-estimation by patients. 
The study evaluated effect of communication style (verbal vs verbal + numeric) on 
perception of risk of experiencing medication side effects of different frequency and 
severity levels. METHODS: Participants were randomly presented with information 
on medication side effects using either verbal (e.g. ‘rarely’) or verbal + numeric (e.g. 
‘rarely i.e. 2 out of 100’) communication style for frequency descriptions, in a 2 (com-
munication style: verbal, verbal combined with numeric frequency) X 2 (side effect 
frequency: low, high) X 2 (side effect severity: mild, severe) experimental design. 
Perception of risk of experiencing side effects was measured and test for analysis 
of variance was performed. RESULTS: Communication style was observed to sig-
nificantly affect risk perception for certain combinations of severity and frequency. 
It was observed that with combined communication style (verbal + numeric), risk 
perception of severe side effects of low frequency decreased (mean difference: 11.24; 
C.L.: 4.60 – 17.82) whereas that of mild side effects of high frequency side increased 
(mean difference: 7.80; C.L.: 1.21 – 14.39) as compared to only verbal communication 
style. It was also observed that the low and high frequency side effects were better 
distinguished with respect to their risk when combined communication style was 
used (mean risk perception difference between low and high frequency side effects: 
36.24; C.L.: 31.58 – 40.89) as compared to verbal only (mean difference: 22.2; C.L.: 
17.53 – 26.84). Significant main effects of frequency and severity on risk perception 
were also observed. CONCLUSIONS: Use of numeric frequencies along with ver-
bal descriptions of risk of medication side effect helps in better understanding of 
underlying risk and reduces its over-estimation, especially for low frequency side 
effects. Healthcare professionals should take into consideration these effects while 
communicating side-effect risks to their patients.
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OBJECTIVES: In 2006 a number of studies were conducted in Kazakhstan with 
UNICEF, which have shown that the majority of children in children’s homes are at 
risk of essential nutrients deficiency. So we have investigated a nutrition adequacy 
according to the body needs of the orphans and children left without parental 
care in children’s homes of the health care system. METHODS: Were included 226 
children from national orphan homes in Akmola and Almaty regions in the ages 
of 6 to 36 months. The study did not include children with disabilities or severe 
diseases. 100 children (57 boys, 43 girls) from the families in organized groups 
were taken as control group. Were evaluated a physiological status, hemoglobin, 
morphofunctional status of the children, also the analysis of food packages and 
the chemical composition of the diet were done. Malnutrition was calculated by 
“Anthro” program (WHO, 2006). RESULTS: Birth weight corresponded to normal in 
67% of children under parental care and 33% of orphans, 56% of orphans are lag-
ging in teething development, in the control group was no lag (1%). 15% of orphans 
have clinical manifestations of changes in the skin, mucous membranes and bone. 
Consumption of the main types of products (primarily meat, milk, fish, vegetables 
and fruit) in children’s homes was below current standards and recommendations 
of the Kazakh Academy of Nutrition, based on international experience. Because of 
inadequate food intake, the orphans have an expressed protein deficit (25%), PUFAs 
(32%), vitamin A (44%), pyridoxine (45%), pantothenic acid (53%), vitamin B12 (37 %), 
ascorbic acid (59%) and copper. CONCLUSIONS: Analysis showed that the actual 
children nutrition scheme is obsolete and needs to be revised in a short time. The 
study will have indices of more in-depth clinical examination and QoL evaluation 
with further economical calculation (budget impact, etc.)
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